MichaelCharlesSnabesMDPhD

Obstetrics & Gynecology • Abbott Park, IL

Reproductive Endocrinology & Infertility, STD Gynecology

Senior Medical Director, Clinical Development, General Medicine, AbbVie Pharmaceuticals

Join to view full profile

Dr. Snabes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Snabes' full profile

Already have an account?

Office
1 N Waukegan Rd
Bldg 30
Abbott Park, IL 60064

Education & Training

Baylor College of MedicinePost-Doctoral Fellowship, 1991 - 1994
Baylor College of MedicineFellowship, Reproductive Endocrinology and Infertility, 1990 - 1992
Baylor College of MedicineResidency, Obstetrics and Gynecology, 1987 - 1990
Baylor College of MedicineInternship, Transitional Year, 1986 - 1987
The University of Texas Health Science Center at San AntonioClass of 1986
Baylor College of MedicinePost-Doctoral Fellowship, 1978 - 1982
University of MichiganPh.D., Physiology, 1972 - 1978

Certifications & Licensure

IL State Medical License 1998 - 2026
TX State Medical License 1987 - 2025

Awards, Honors, & Recognition

Alpha Omega Alpha Honor Medical Society 1984
Fellow (FACS) American College of Surgeons
Fellow (FACOG) American Congress of Obstetricians and Gynecologists
Fellow (FACE) American Association of Clinical Endocrinology
Join now to see all

Clinical Trials

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women Start of enrollment: 2008 Jan 01
Completed
Phase 3
Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Start of enrollment: 2006 Dec 01
Completed
Phase 3
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women Start of enrollment: 2008 Mar 01
Completed
Phase 3
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) Start of enrollment: 2010 Oct 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

1 citations
Efficacy, tolerability, and bone density outcomes of elagolix with add-back therapy for endometriosis-associated pain: twelve months of an ongoing randomized phase 3 t...
Charles E Miller, Jin Hee Kim, Robin Kroll, James A Simon, Ahmed M Soliman
American Journal of Obstetrics and Gynecology. 2024-12-01
Impact of demographic and clinical factors on elagolix plus add-back therapy effects on patient-reported nonbleeding symptoms in women with heavy menstrual bleeding an...
James A Simon, Elizabeth A Stewart, Susan Jewell, Moming Li, Michael C Snabes
F&S Reports. 2024-09-01
10 citations
Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical Trial.
Shalender Bhasin, A Michael Lincoff, Steven E Nissen, Kathleen Wannemuehler, Marie E McDonnell
JAMA Internal Medicine. 2024-04-01

Press Mentions

Clinical Pharmacology of Elagolix: An Oral Gonadotropin-Releasing Hormone Receptor Antagonist for EndometriosisAugust 7th, 2020

Professional Memberships